New directions in the treatment of colorectal cancera look to the future

European Journal of Cancer

Volumn 36, Issue 5, 2000, Pages 559-566

  Sobrero, A ^f   Kerr, D ^a   Glimelius, B ^f   Van Cutsem, E ^b   Milano, G ^c   Pritchard, D M ^f   Rougier, P ^d   Aapro, M ^e  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c CENTRE ANTOINE LACASSAGNE   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

^e EUROPEAN SCHOOL OF ONCOLOGY   (Italy)

^f NONE

Author keywords

5 FU; Apoptosis; Capecitabine; Colorectal cancer; Dihydropyrimidine dehydrogenase; Ethynyluracil; Irinotecan; Mitomycin; Oxaliplatin; p53; S1; Thymidylate synthase; UFT

Indexed keywords

5 ETHYNYLURACIL; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; DIHYDROPYRIMIDINE DEHYDROGENASE; ENZYME INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PROTEIN BCL 2; PROTEIN P53; RALTITREXED; UFT;

APOPTOSIS; ARTICLE; CHEMOTHERAPY; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESISTANCE; ENZYME ACTIVITY; GENE MUTATION; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; SURVIVAL RATE; SURVIVAL TIME;

ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FLUOROURACIL; HUMANS; PATIENT SATISFACTION; SURVIVAL ANALYSIS;

EID: 0034066520     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00314-7     Document Type: Article

References (59)

1. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer. a randomized trial J. Clin. Oncol. 10:1992;904-911.
2. Sheithauer W., Rosen H., Kornek G.V., Sebesta C., Depish D. Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br. Med. J. 306:1993;752-755.
3. Glimelius B., Hoffman K., Graf W.et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann. Oncol. 6:1995;267-274.
4. Rougier P., Laplanche A., Huguier M.et al. Hepatic arterial infusion of floxouridine in patients with liver metastases from colorectal carcinoma. long-term results of a prospective randomized trial J. Clin. Oncol. 10:1992;1112-1118.
5. Allen-Mersh T.G., Earlam S., Fordy C., Abrams K., Houghton J. Quality of life and survival with continuous hepatic-artery floxouridine infusion for colorectal liver metastases. Lancet. 344:1994;1255-1260.
6. Glimelius B., Graf W., Hoffman K., Påhlman L., Sjïdén P.O., Wennberg A. General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. a longitudinal study Acta Oncol. 31:1992;645-651.
7. Graf W., Glimelius B., Påhlman L., Bergstróm R. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br. J. Cancer. 70:1994;559-563.
8. Fages B, Cote C, Gruia G, Jacques C, Awad L, Herait P. Tumor response and stabilization rates are worthwhile surrogate efficacy endpoints in metastatic colorectal cancer (CRC). Analysis of data in 455 5-FU resistant patients treated with CPT-11. ASCO 1997, 1022.
9. Sequential methotrexate/5-fluorouracil/leucovorin (MFL) is superior to 5-fluorouracil alone in advanced symptomatic colorectal carcinoma. A randomized trial. J. Clin. Oncol. 7:1989;1437-1446.
10. Biochemical modulation of 5-fluorouracil. a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer Ann. Oncol. 4:1993;235-241.
11. Glimelius B., Hoffman K., Páhlman L.et al. Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide antigen specific (TPS) measurements. Acta Oncol. 35:1996;141-148.
12. Von Hoff D.D. There are no bad anticancer agents, only bad clinical trial designs. Clin. Cancer Res. 4:1998;1079-1086.
13. Ratain MJ. Development of target based antineoplastic agents. Educ Book ASCO 1999, 71-75.
14. Johnston P.G., Fisher E.R., Rockette H.E.et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol. 12:1997;2640-2647.
15. Aschele C., Debernardis D., Casazza S.et al. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J. Clin. Oncol. 17:1999;1760-1770.
16. Dive C., Hickman J.A. Drug target interactions. only the first step in the commitment to a programmed cell death Br. J. Cancer. 64:1991;192-196.
17. Brett M.C., Pickard N., Green B.et al. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur. J. Surg. Oncol. 2:1996;182-185.
18. Potten C.S. What is an apoptotic index measuring? A commentary. Br. J. Cancer. 74:1996;1743-1748.
19. Pritchard D.M., Watson A.J.M. Apoptosis and gastrointestinal pharmacology. Pharmacol. Ther. 72:1996;149-169.
20. Jacobs T.W., Prioleau J.E., Stillman I.E., Schnitt S.J. Loss of tumor marker immunostaining intensity on stored paraffin slides of breast cancer. J. Natl Cancer Inst. 88:1996;1054-1059.
21. Beck A., Etienne M.C., Cheradame S.et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur. J. Cancer. 30A:1994;1517-1522.
22. Etienne M.C., Cheradame S., Fischel J.L.et al. Response to fluorouracil therapy in cancer patients. the role of tumoral dihydropyrimidine dehydrogenase activity J. Clin. Oncol. 13:1995;1663-1670.
23. Danenberg K, Salonga J, Park J, et al. Dihydropyrimidine dehydrogenase and thymidylate synthase gene expression identify a high percentage of colorectal tumors responding to FU. Proc Am Soc Clin Oncol 1998, 17, abstr 992.
24. Diasio R.B., Harris B.E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinetic. 16:1989;215-237.
25. Etienne M.C., Lagrange J.L., Dassonville O.et al. A population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol. 12:1994;2248-2253.
26. Cao S., Rustum Y.M., Spector T. 5-Ethynyluracil (776C85). modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma Cancer Res. 54:1994;1507-1510.
27. Baker S.D., Khor S.P., Adjei A.A.et al. Pharmacokinetic, oral bioavailability and safety study of 5-fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J. Clin. Oncol. 14:1996;3085-3096.
28. Rustum Y.M., Harstrick A., Cao S.et al. Thymidylate synthase inhibitors in cancer therapy. direct and indirect inhibitors J. Clin. Oncol. 15:1997;389-400.
29. Findlay M., Van Cutsem E., Kocha W.et al. A randomized phase II of Xeloda (capecitabine) in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 16:1997;227a.
30. Cox J.V., Pazdur R., Thibault A.et al. A phase III trial of Xeloda in previously untreated advanced metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 18:1999;1016.
31. Carmichael J., Popiela T., Radstone D.et al. Randomized comparative study of orzel (oral uracil/tegafur) plus LV versus parenteral FU in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 18:1999;1015.
32. Pritchard D.M., Watson A.J.M., Potten C.S., Jackman A.L., Hickman J.A. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil. evidence for the involvment of RNA perturbation Proc. Natl. Acad. Sci. USA. 94:1997;1795-1799.
33. Pritchard DM, Potten CS, Hickman JA. The relationship between p53-dependent apoptosis, inhibition of proliferation and 5-fluorouracil-induced histopathology in murine intestinal epithelia. Cancer Res, 1998, 58, 5453-5465.
34. Sobrero A., Aschele C., Bertino J. Fluorouracil in colorectal cancer. A tale of two drugs. implications for biochemical modulation J. Clin. Oncol. 15:1997;368-381.
35. Aschele C., Sobrero A., Faderan M.A.et al. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 52:1992;1855-1864.
36. Sobrero A., Aschele C., Guglielmi A.et al. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J. Natl. Cancer Inst. 85:1993;1937-1944.
37. Louvet C., De Gramont A., Bennamoun M. High dose folinic acid, 5-fluorouracil bolus and continuous infusion in metastatic colorectal cancer. a 3-day/3-week schedule Eur. J. Cancer. 28:1992;611-612.
38. Sobrero A., Aschele C., Guglielmi A.et al. Schedule-selective biochemical modulation of 5-fluorouracil. a phase II study in advanced colorectal cancer Clin. Cancer Res. 1:1995;955-960.
39. Sobrero A, Frassineti GL, Giulani R, et al. Randomized comparison between sequential MTX→FU and schedule specific biochemical modulation in advanced colorectal cancer (ACRC). 23rd Congress Eur Soc Med Oncol 1998, 33 abstract 157.O.
40. Lévi F.A., Zidani R., Vannetzel J-M.et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases. a randomized multi-institutional trial J. Natl. Cancer Inst. 86:1994;1608-1617.
41. Lévi F., Zidani R., Misset J.L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 350:1997;681-686.
42. Bertheault-Cvitkovic F., Jami A., Ithzaki M.et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol. 14:1996;2950-2958.
43. Kemeny M.M., Adak S., Lipsitz S.et al. Prospective randomized study of surgery alone versus continuous hepatic artery infusion of FUDR and continuous systemic infusion of FU after resection for colorectal liver metastases. Proc. Am. Soc. Clin. Oncol. 18:1999;1012.
44. Kemeny N., Cohen A., Huang Y.et al. Randomized study of hepatic artery infusion and systemic chemotherapy versus systemic chemotherapy alone as adjuvant therapy after resection of hepatic metastases from colorectal carcinoma. Proc. Am. Soc. Clin. Oncol. 18:1999;1011.
45. Cunningham D., Pyrhönen S., James D.et al. The value of second line chemotherapy after Fluorouracil failure for patients with metastatic colorectal cancer. a randomized phase III trial of irinotecan versus supportive care Proc. Am. Soc. Clin. Oncol. 17:1998;1a.
46. Van Cutsem E., Bajetta E., Niederle N.et al. A phase III multicenter randomized trial comparing CPT-11 to infusional 5-FU regimen in patients with advanced colorectal cancer after 5-FU failure. Proc. Am. Soc. Clin. Oncol. 17:1998;256a.
47. Cunningham D., Pyrhonen S., James R.D.et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 352:1998;1413-1418.
48. Rougier P., Vancustem E., Bajetta E.et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 352:1998;1407-1412.
49. Saltz L.B., Locker P.K., Pirotta N.et al. Weekly irinotecan, leucovorin and FU is superior to daily X 5 LVFU in patients with previously untreated metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 18:1999;898.
50. Douillard J.Y., Cunningham D., Roth A.D.et al. A randomized phase III trial comparing irinotecan+FU folinic acid to the same schedule of FUFA in patients with metastatic colorectal cancer as front line chemotherapy. Proc. Am. Soc. Clin. Oncol. 18:1999;899.
51. De Gramont A., Vignoud J., Tournigand C.et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48 h continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer. 33:1997;214-219.
52. De Gramont A., Figer A., Seymour M.et al. A randomized trial of leucovorin (LV) and 5-fluorouracil (5-FU) with or without oxaliplatin in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 17:1998;257a.
53. Price T., Cunningham D., Hickish T.et al. Phase III study of chronomodulated vs protracted venous infusional FU both combined with mitomycin in first line therapy for advanced colorectal carcinoma. Proc. Am. Soc. Clin. Oncol. 18:1999;1008.
54. Van Cutsem E. Future developments with 'Tomudex' (raltitrexed). Anti-Cancer Drugs. 8:1997;S33-S38.
55. Van Cutsem E. A glimpse of the future. New directions in the treatment of colorectal cancer. Eur. J. Cancer. 32A:1996;S23-S27.
56. Nemunaitis J., Poole C., Primrose J.et al. Combined Analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer. selection of a biologically active and tolerable dose for longer-term studies Clin. Cancer Res. 4:1998;1101-1109.
57. Cole D.J., Baron P.L., O'Brien P., Reed C., Tsang K.Y., Schlom J. Phase 1 study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge. Human Gene Ther. 7:1996;1381-1394.
58. Green N.K., Searle P.F., Young L.S., Kerr D.J., Neoptolemos J.P. Gene therapy for gastrointestinal cancer. GI Cancer. 2:1996;43-53.
59. Huber B.E., Austin E.A., Good S.S.et al. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res. 53:1993;4619-4626.